<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003898</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067069</org_study_id>
    <secondary_id>RPCI-RP-9810</secondary_id>
    <nct_id>NCT00003898</nct_id>
  </id_info>
  <brief_title>Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation</brief_title>
  <official_title>The Use of Supplemental Oral Glutamine (GLN) to Decrease Morbidity in Patients Undergoing Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Glutamine may be able to decrease inflammation of the mouth and digestive system
      in children who are undergoing stem cell transplantation.

      PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of glutamine in
      reducing inflammation of the mouth and digestive system in children who are undergoing
      peripheral stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of supplemental oral glutamine in reducing the severity
      and duration of mucositis in children undergoing stem cell transplantation. II. Determine the
      safety of this regimen in these patients. III. Determine serum glutamine levels achieved
      during this regimen in these patients.

      OUTLINE: This is a randomized, double blind, multicenter study. Patients are stratified
      according to inclusion of total body irradiation in the conditioning regimen (yes vs no).
      Patients receive either oral glutamine or oral placebo (glycine) twice a day beginning on the
      day of admission for the stem cell transplant and continuing for 28 days or until hospital
      discharge, whichever is first.

      PROJECTED ACCRUAL: A total of 120 patients (60 per arm) will be accrued for this study within
      2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">120</enrollment>
  <condition>Oral Complications</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glutamine</intervention_name>
    <description>Oral</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Undergoing allogeneic or autologous stem cell transplant
        (including bone marrow, cord blood, or peripheral blood stem cells) Conditioning regimen
        must have at least 50% risk of grade III or IV mucositis No grade III or IV hepatic
        toxicity

        PATIENT CHARACTERISTICS: Age: 1 to 21 Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: See Disease Characteristics Renal: Not
        specified Other: No grade III or IV toxicity at admission for stem cell transplant No
        altered mental status

        PRIOR CONCURRENT THERAPY: No concurrent vancomycin paste or nonabsorbable antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Jean Bambach, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Aquino VM, Harvey A, Garvin J, et al.: The use of supplemental glutamine to decrease morbidity in children undergoing stem cell transplantation: a Pediatric Blood and Marrow Transplant Consortium study. [Abstract] 2004 Pediatric Academic Societies' Annual Meeting, May 1-4, San Francisco, California. A-1627, 2004. Availabel online Last accessed August 29, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, Jackson GB, Sandler ES. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2005 Oct;36(7):611-6.</citation>
    <PMID>16086046</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2004</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Barbara Bambech, MD</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>oral complications</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

